XOMA CORP
NASDAQ: XOMAP (XOMA Royalty Corporation - 8.62)
Last update: 16 hours ago26.35
-0.05 (-0.18%)
| Previous Close | 26.40 |
| Open | 26.35 |
| Volume | 1,822 |
| Avg. Volume (3M) | 1,356 |
| Price / Earnings (TTM) | 26.32 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| TTM Dividend Yield | 8.18% |
| Profit Margin | -6.66% |
| Operating Margin (TTM) | 37.26% |
| Diluted EPS (TTM) | 1.00 |
| Quarterly Revenue Growth (YOY) | 967.90% |
| Total Debt/Equity (MRQ) | 135.24% |
| Current Ratio (MRQ) | 5.54 |
| Operating Cash Flow (TTM) | -6.60 M |
| Levered Free Cash Flow (TTM) | -31.29 M |
| Return on Assets (TTM) | -6.78% |
| Return on Equity (TTM) | -3.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | XOMA Royalty Corporation - 8.62 | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Institutions | 1.82% |
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements |
| 17 Oct 2025 | Announcement | XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement |
| 02 Oct 2025 | Announcement | XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. |
| 22 Sep 2025 | Announcement | XOMA Royalty Declares Quarterly Preferred Stock Dividends |
| 17 Sep 2025 | Announcement | XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc. |
| 03 Sep 2025 | Announcement | XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference |
| 20 Aug 2025 | Announcement | Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share |
| 13 Aug 2025 | Announcement | XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements |
| TTM Dividend Yield | 8.18% |
| 4Y Average Dividend Yield | 8.09% |
| Expected Next Dividend Payment | Jan 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 03 Oct 2025 | 31 Jul 2025 | 15 Oct 2025 | 0.53906 Cash |
| 03 Jul 2025 | 21 May 2025 | 15 Jul 2025 | 0.53906 Cash |
| 03 Apr 2025 | 26 Feb 2025 | 15 Apr 2025 | 0.53906 Cash |
| 03 Jan 2025 | 23 Oct 2024 | 15 Jan 2025 | 0.53906 Cash |
| 03 Oct 2024 | 24 Jul 2024 | 15 Oct 2024 | 0.53906 Cash |
| 03 Jul 2024 | 15 May 2024 | 15 Jul 2024 | 0.53906 Cash |
| 02 Apr 2024 | 21 Feb 2024 | 15 Apr 2024 | 0.53906 Cash |
| 02 Jan 2024 | 18 Oct 2023 | 16 Jan 2024 | 0.53906 Cash |
| 04 Oct 2023 | 26 Jul 2023 | 16 Oct 2023 | 0.53906 Cash |
| 30 Jun 2023 | 17 May 2023 | 17 Jul 2023 | 0.53906 Cash |
| 03 Apr 2023 | 22 Feb 2023 | 17 Apr 2023 | 0.53906 Cash |
| 03 Jan 2023 | 26 Oct 2022 | 17 Jan 2023 | 0.53906 Cash |
| 30 Sep 2022 | 20 Jul 2022 | 17 Oct 2022 | 0.53906 Cash |
| 30 Jun 2022 | 18 May 2022 | 15 Jul 2022 | 0.53906 Cash |
| 31 Mar 2022 | 17 Mar 2022 | 15 Apr 2022 | 0.53906 Cash |
| 03 Jan 2022 | 01 Dec 2021 | 17 Jan 2022 | 0.53906 Cash |
| 30 Sep 2021 | 28 Jul 2021 | 15 Oct 2021 | 0.53906 Cash |
| 01 Jul 2021 | 21 May 2021 | 15 Jul 2021 | 0.53906 Cash |
| 31 Mar 2021 | 17 Mar 2021 | 15 Apr 2021 | 0.71875 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2025 | 2.16 | 4 | 8.18 |
| 2024 | 2.16 | 4 | 8.33 |
| 2023 | 2.16 | 4 | 8.49 |
| 2022 | 2.16 | 4 | 8.69 |
| 2021 | 1.80 | 3 | 6.83 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |